Jaskamal Kahlon, MD
Interventional Cardiology · Mesa, AZNPI 1093783953
Payments from drug & device makers
What this record shows
20 manufacturers reported payments, led by Edwards Lifesciences at 38.5% of the total. Reporting peaked in 2024 at $3,349 and has fallen 63.0% since, to $1,238 in 2025.
Across 179 payments — averaging $82.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$6K
- Abbott$4K
- Medtronic$2K
- Shockwave Medical, Inc$736
- Cardiovascular Systems Inc.$716
- Abiomed$380
- plus $1K from 14 others
Across 10 payments — averaging $18,688 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$187K
What the payments were for
- Travel & lodging$6,30843%
- Food & beverage$8,52157%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 46 | $5,705 |
| Abbott | 69 | $4,445 |
| Medtronic(2 entities) | 20 | $1,613 |
| Shockwave Medical, Inc | 4 | $736 |
| Cardiovascular Systems Inc. | 8 | $716 |
| Abiomed | 4 | $380 |
| Bard Peripheral Vascular, Inc. | 6 | $323 |
| Boston Scientific | 6 | $237 |
| AstraZeneca | 2 | $230 |
| Novartis | 1 | $123 |
| Venclose Inc. | 2 | $87 |
| Heartflow, Inc. | 3 | $61 |
| Atricure, Inc. | 1 | $35 |
| Angiodynamics, Inc. | 1 | $28 |
| Philips North America LLC | 1 | $23 |
| Cvrx, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $20 |
| Cardiva Medical, Inc. | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $17 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,575
- PASCAL$1,353
- Mitra Clip system$1,288
- EVOQUE$1,113
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$736
- Peripheral Orbital Atherectomy System$509
- Coronary Orbital Atherectomy System$509
- SAPIEN 3 Ultra RESILIA$500
- MitraClip$446
- SYMPLICITY G3$280
- Impella$253
- CoreValve Evolut$197
- Resolute$166
- PORTICO$150
- RotarexS 6 F x 135 cm$149
- TRICLIP$148
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$132
- ENSITE$129
- CARDIOMEMS$125
- LEQVIO$123
How this compares
$14,829 in reported general payments places this provider in the 55th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,100 | $1,458,339 |
| XareltoRivaroxaban | 201 | $267,910 |
| EntrestoSacubitril/Valsartan | 73 | $84,087 |
| Repatha SureclickEvolocumab | 71 | $79,583 |
| Rosuvastatin Calcium | 1,485 | $23,612 |
| ClopidogrelClopidogrel Bisulfate | 1,115 | $15,208 |
| BrilintaTicagrelor | 13 | $14,710 |
| Metoprolol Succinate | 1,150 | $13,202 |
| Clonidine | 58 | $9,935 |
| Atorvastatin Calcium | 917 | $9,384 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 305 | $7,558 |
| Olmesartan Medoxomil | 385 | $7,310 |
| Ranolazine ErRanolazine | 66 | $6,358 |
| Repatha SyringeEvolocumab | 11 | $5,796 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 20 | $5,734 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $123 | $84,08773 claims |
| AstraZenecaBrilinta | $230 | $14,71013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Mesa
- Faraj KargoliMesa$115K
- Nachiket PatelMesa$107K
- Satya Prakash AtmakuriMesa$41K
- Robert CandipanMesa$32K
- I-Hui ChiangMesa$27K
- Paul SorajjaPhoenix$1.1M
- Hursh NaikAvondale$781K
- Thomas WaggonerTucson$617K
- Timothy ByrnePhoenix$614K
- Haidar YassinPhoenix$434K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.